Close Menu

NanoString

The company said that more than 95 percent of eligible early-stage breast cancer patients can now have the test paid by insurance.

The shelf registration follows a recent $56.5 million financing and comes amid an expansion of the firm's commercial operations.

NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.

NanoString also beat analyst estimates on the top and bottom lines, and upped its revenue guidance for the year based primarily on collaboration revenues.

The Index gained 2 percent in June, outperforming the Dow and the Nasdaq, but underperforming the Nasdaq Biotechnology Index, which gained nearly 9 percent.

New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.

The offering was underwritten by RW Baird, and Nanostring said it plans to use the proceeds for general corporate purposes and working capital.

The company will sell 3 million shares with RW Baird as the sole underwriter of the offering, with a 30-day option to purchase an additional 450,000 shares.

The PAM50 breast cancer classifier successfully split prostate cancer samples into luminal and basal subtypes with ties to patient outcomes and treatment response.

Revenue increased in all of the firm's sectors, driven by growth in the installed base for its nCounter systems, as well as increases in consumables sales.

Pages

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.